Open AccessThalidomide for the treatment of angiodysplasia‐related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?
Author(s) -
Patel Harish,
Mehershahi Shehriyar,
Shaikh Danial Haris,
Makker Jasbir,
Nayudu Sureshkumar,
Remy Prospere,
Chilimuri Sridhar
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2501
Subject(s) - medicine , thalidomide , angiodysplasia , refractory (planetary science) , gastrointestinal bleeding , surgery , gastroenterology , multiple myeloma , physics , astrobiology
Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose‐dependent. The low‐dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.